Clinical Trials Logo

ALK Gene Translocation clinical trials

View clinical trials related to ALK Gene Translocation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02201992 Recruiting - Clinical trials for Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Start date: March 23, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.